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Hormonal Therapy and Preventive Care
of Transgender Patients
Angela Chu, Jana Randolph, Austin Hopkins, Victoria Cho, Sophocles Chrissobolis, Ph.D.

Abstract
Transgenderism occurs when an individual's gender identity
conflicts with the individual's biological sex. A variety of
methods may be used in order to reconcile this disparity in
transgender individuals including psychological counseling,
cross-sex hormone therapy and sex reassignment surgery.
The most important role for pharmacists in the treatment of
transgender patients is in dispensing hormonal medications
for cross-sex treatment. Hormone therapy may be used to
suppress characteristics of the patient's biological sex as well
as to induce development of characteristics that correlate
with the patient's gender identity. In male-to-female (MtF)
transgender patients, the most commonly used medications
include agents which suppress testosterone such as mineralocorticoid receptor antagonists and gonadotropin-reieasing
hormone (GnRH) agonists. This is in addition to estrogen
therapy, which causes feminization. By far the most commonly used medication for female-to-male (FtM) transgender patients is testosterone to induce masculinization.
Medroxyprogesterone or GnRH agonists may also be used in
FtM patients to suppress female characteristics. Pharmacists
should be aware of the risks associated with cross-sex
hormone therapy in transgender patients as well as the side
effects and monitoring required for these therapies. Pharmacists may also play a role in being able to recognize signs of
appropriate feminization or masculinization in MtF and FtM
patients.
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criteria for gender dysphoria. Health care providers should
use the criteria to identify if an individual who claims to be
transgender meets the criteria of gender dysphoria, not necessarily transgenderism itself. If the individual meets the
DSM-5 criteria, only then should therapy be initiated. Currently, the DSM-4 and V should not be considered mutually
exclusive. The two criteria build on one another, providing a
better case for an individual who identifies as transgender.
The DSM-4 criteria are established on diagnosing gender
dysphoria rather than transgenderism. The DSM-5 criteria
are an established set of behaviors observed in individuals
with gender dysphoria in which the more criteria that are
met, the stronger the indication for gender dysphoria.2 The
DSM-4 criteria for gender dysphoria in adolescents and
adults follows (adapted from Belluardo-Crosby and LillisZ):
• A resilient and adamant identification with the opposite gender (not merely a desire for any perceived cultural advantages of being the other sex). In children,
the disturbance is manifested by four (or more) of the
following:
Repeatedly stated to be, or insistence that he or
she be addressed as the other gender (pronouns of
the other gender);
In boys, preference for cross-dressing or appearing in female attire; in girls, insistence on wearing
only stereotypical masculine clothing (presentation of the other gender);
Strong and persistent preferences for roles in
make-believe play or persistent fantasies of being
the other sex (assuming the role of the other gender);
Intense desire to participate in the stereotypical
games and pastimes of the other sex (further assumption of the role of the other gender);
0
Strong preference for playmates of the other sex
(experiencing interaction with the other gender).
•
Persistent discomfort with his or her sex or sense of
inappropriateness in the gender role of that sex.
• The disturbance is not concurrent with a physical intersex condition (not a biological issue).
• The disturbance causes clinically significant distress or
impairment in social, occupational or other important
areas of functioning.
0

Introduction
In today's changing world, the patient population continues
to increase in its diversity. A recently emerging population is
the transgender population. A transgender individual can be
defined as a person whose gender identity and birth sex are
in conflict with one another. This means a biological female
identifies one's gender as being male, or a biological male
identifies one's gender as being female. When it comes to
transgendered individuals, a majority may experience gender dysphoria, defined as discomfort or distress caused by a
discrepancy between the individual's sex and perceived gender role.1 This differs from gender nonconformity in which
the individual expresses one's gender that differs from the
culture and social norm.
Gender dysphoria can be associated with transgender individuals. A set Diagnostic and Statistical Manual of Mental
Disorder (DSM) criteria does exist for gender dysphoria. It
should be noted that there is controversy with the DSM-5
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What DSM-5 aimed to accomplish compared to DSM-4 included the use of "incongruence" in place of "disorder" and
other patient-friendly language to diminish the stigma that is
often associated with transgenderism and gender dysphoria
being considered mental illness that should be remedied.
Likewise, it humanizes the patients being subjected to the
criteria. Lastly, the language is shifted to note the incongru-
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ence between biology and identity. This allows the focus to be
on matching gender identity to gender presentation. 2
The DSM-5 criteria for gender dysphoria in adolescents and
adults follows (adapted from Belluardo-Crosby and Lillis 2):
• A separation between one's expressed gender and assigned sex of at least six months' duration, as marked
by at least two of the following:
Incongruence
between
one's
experienced/
expressed gender and primary/secondary sex
characteristics (or, in prepubescent adolescents,
the foreseen secondary sex characteristics);
Strong desire to be rid of one's current sex characteristics because of a marked dissociation with
one's expressed gender (or, in prepubescent adolescents, a desire to prevent the development of
the expected secondary sex characteristics following puberty);
Strong desire for the primary and/or secondary
sex characteristics of the other biological sex;
Strong desire to be or present as the other gender
(or some alternative gender different from one's
assigned gender);
Strong desire to adapt or change the other gender
and its societal role (or some alternative gender
different from one's assigned gender);
Strong principle that one has the typical feelings
and reactions of the other gender (or some alternative gender different from one's assigned gender);
• The condition is associated with clinically significant
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misery or dysfunction in activities of daily living or
with a significantly increased risk of suffering such as
distress or disability.
The following discusses treatment options, monitoring parameters and risk prevention strategies related to transitioning the patient between male-to-female (MtF) and female-tomale (FtM), and the role a pharmacist has in this transition.

0

0

Male-to-Female (MtF)
Testosterone Suppression
Male-to-female hormone therapy begins with an antiandrogen agent to reduce the amount of natural testosterone produced. This is achieved with spironolactone (oral, 100-200
mg/d), a mineralocorticoid receptor antagonist that produces
decreased testosterone production.3 Spironolactone is contraindicated in patients with renal failure; therefore, monitoring for hypotension, hyponatremia, hyperkalemia and renal
function should be done throughout the first week, every
month for three months, and then every three months.4 Gonadotropin-releasing hormone (GnRH) agonists can also be
used to suppress testosterone production, in that they result
in receptor down-regulation, ultimately resulting in reduced
testosterone levels. These GnRH agonists also reduce testosterone levels through a complex negative feedback mechanism whereby excess testosterone production results in
suppression of the hypothalamic-pituitary-gonadal axis, thus
ultimately resulting in reduced testosterone levels (Figure
l).s The only agent studied and reportedly displaying clinical
efficacy is goserelin, given 3.6 mg subcutaneously every 28

Figure 1. Negative Feedback Mechanism with GnRH Stimulation.s
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Gonadotropin-releasing hormone (GnRH) is released from the hypothalamus to the anterior pituitary gland to stimulate the
release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). Luteinizing hormone acts on Leydig cells in the
testes to produce testosterone which contributes to spermatogenesis. Follicle stimulating hormone acts on Sertoli cells in the
testes to contribute to spermatogenesis. Gonadotropin-releasing hormone agonists, such as goserelin, result in receptor
down-regulation, ultimately resulting in reduced testosterone levels. Gonadotropin-releasing hormone agonists also lead to
increased levels of FSH, LH and testosterone resulting in negative feedback to ultimately decrease endogenous GnRH, FSH
and LH release and their downstream effects.
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days.3 Adverse effects in men are minimal compared to
women, but hypercalcemia and hyperglycemia should be
monitored.6 In either therapy, testosterone levels should be
assessed every three months until in the normal female
range (15-70 ng/dL).7
Estrogen
Estrogen therapy can be initiated simultaneously with testosterone suppression, but is most effective when ideal testosterone levels have been achieved.3 Estrogen forms vary
but are equally effective and can be chosen based on patient
preference. Common dosage forms and doses are as follows:
oral estradiol (2-6 mg/d), transdermal estradiol (0.1-0.4 mg
twice weekly), intramuscular estradiol valerate (5-20 mg
every two weeks) or intramuscular estradiol cypionate (2-10
mg weekly). Estrogen levels should be monitored every three
months with testosterone and kept within normal female
range, ideally <200 pg/ml.8 Antiandrogen and estrogen therapies will have noticeable feminizing effects on patients
within three to six months of initiation.9 These include a decrease in hair growth, libido, spermatogenesis, erection, testicle size and muscle mass, and an increase in breast growth,
nipple size and fat distribution.
Clinical and Lab Monitoring
Regular monitoring of serum electrolytes (specifically sodium, calcium and potassium), liver function, renal function,
lipids, complete blood cell count, blood pressure, weight and
a physical exam should occur pretherapy and every three
months in the first year of therapy and then at least once annually.3
Surgical Options
If the patient is considering sexual reassignment surgery, the
patient should be adherent to hormone therapy for at least
one year prior to surgery to ensure drug therapy adherence
thereafter for life.3 The patient should also have a committed
surgeon and physician who will prescribe and monitor established hormone therapy. Surgical options for MtF patients
include breast augmentation, facial reconstruction, orchiectomy (removal of the testes) or penile disassembly
(repositioning the skin, nerves and blood supply of the penis
to form female parts) followed by vaginoplasty, clitoroplasty
and urethral repositioning.10 Noninvasive interventions can
be coupled with surgery to further feminize the MtF patient,
including voice therapy to adjust voice pitch and laser hair
removal.3 Following surgery, estrogen therapy needs to be
continued.
Risks and Prevention
In women, unopposed estrogen has been known to increase
the risk of breast cancer, hypertension, cerebrovascular disease and cardiovascular disease, including cardiovascular
events such as venous thromboembolism and myocardial
infarction.11 In transgender patients, an increased risk of the
same cardiovascular events has been documented in multiple studies due to estrogen therapy.12-1s Lifestyle factors such
as smoking and sedentary lifestyle further exacerbate these
risks. 9 However, in patients also taking spironolactone for its
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antiandrogen properties, hypertension may not be an issue
because spironolactone is a mineralocorticoid receptor antagonist that results in increased sodium, chloride and water
excretion and thus decreased blood pressure. Routine monitoring of vital signs (specifically blood pressure) and a physical assessment should be done at each office visit to reduce
the risk of cardiovascular events.
No long-term study on transgender patients has been
conducted to adequately describe if MtF patients are at an
increased risk of breast cancer.3 The Endocrine Society
guidelines recommend that all MtF patients still follow routine breast, prostate and colon cancer screenings to minimize
their risk. An increase in prolactin levels has been documented with estrogen stimulating the pituitary gland to produce
more lactotrophs (cells in the pituitary gland that secrete
prolactin) leading to an enlarged gland. Excess prolactin levels have the additional effect of decreasing GnRH release to
suppress testosterone production which is desired in these
patients. Despite these desired effects, prolactin levels
should still be monitored at baseline prior to estrogen therapy, in one year and biannually thereafter for development of
prolactinoma. Transient liver enzyme elevations of three
times the upper limit of normal and cholecystitis
(inflammation of the gallbladder from bile buildup) can be
increased; hence, liver function tests should be performed at
least annually.
The MtF patients do not present an increased or decreased
risk for hypercholesterolemia, diabetes, osteoporosis or other chronic disease states uncommon to their existing risk
factors or sex.3 Therefore, health care professionals should
monitor, treat and educate on these conditions based on the
individual patient's health profile following standard guidelines.
Female-to-Male (FtM)
Testosterone
The main cross-sex hormone therapy used for FtM
transgender individuals is testosterone.3 Transdermal or
parenteral dosage forms may be used, and the regimens follow the principles used to treat hypogonadism in men. Testosterone is an endogenous androgen which acts to promote
growth of male sex organs and maintain secondary sex characteristics.16 Some effects of testosterone therapy in FtM
transgender patients are the same as the effects that occur in
hypogonadal men including increased muscle tissue, decreased fat tissue, increased body and facial hair, increased
acne, male pattern baldness and increased libido.3 Effects of
testosterone therapy that occur specifically in FtM patients
include clitoromegaly, decreased fertility, deepening of voice,
and cessation of menses. In the Endocrine Society guidelines,
specific testosterone formulations listed include intramuscular testosterone enanthate and testosterone cypionate, transdermal testosterone 1 percent gel, and testosterone patch. In
addition, although listed in the guidelines as unavailable in
the United States, an intramuscular testosterone formulation
of testosterone undecanoate (Aveed®), was approved by the
U.S. Food and Drug Administration (FDA) in March 2014.17
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This formulation is indicated to treat hypogonadism in
males. Perhaps it may soon be used for the treatment of FtM
transgender patients as well since testosterone treatment in
FtM patients follows the guidelines used for male hypogonadism. Although new to the United States, testosterone
undecanoate has been used safely for FtM treatment in Europe for several years.1s- 20 Suggested doses of different testosterone formulations for FtM transgender patients are
listed in Table i.z1
Monitoring of Testosterone Therapy
Maintaining testosterone levels within the normal male
range (320-1000 ng/dL) is important as levels in the supraphysiological range increase the risk of serious adverse
events which include erythrocytosis, excessive acne and
fluctuation in mood. Rarely, coughing episodes may occur
following intramuscular injection. 21 The Endocrine Society
suggests that physicians measure serum testosterone levels
every two to three months until levels are within the normal
male range.3 For testosterone enanthate and testosterone
cypionate, injections levels should be measured midway between injections, and the dose should be adjusted accordingly if the serum testosterone level is more than 700 ng/dL or
less than 300 ng/dL. For testosterone undecanoate injection,
testosterone levels should be measured just before administration of the next injection. For transdermal testosterone
preparations, testosterone levels may be measured any time
after one week of therapy.
Other Drug Agents
In cases in which testosterone therapy fails to cause cessation of menses, a progestin-like agent such as medroxyprogesterone acetate may be added to the patient's therapy or
endometrial ablation may be performed.3 Medroxyprogesterone induces amenorrhea by transforming a proliferative endometrium into a secretory endometrium.22 Additionally,
depot medroxyprogesterone or GnRH agonists may be administered to FtM patients before beginning testosterone
therapy to decrease the levels of estrogen to the level found
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in biological males.3 The Endocrine Society does not delineate dosing or monitoring parameters for medroxyprogesterone or GnRH therapy in FtM transgender patients.
Gonadotropin-releasing hormone agonists are generally used
in adolescents to suppress development of unwanted sex
characteristics.3 Drug therapy to suppress puberty may begin
after the patient begins exhibiting the physical changes of
puberty, which in girls is when breast development begins.
The GnRH agonists are advantageous for pubertal suppression because their effects are reversible with cessation of
therapy. In girls, GnRH agonists will cause cessation of
menses as well as atrophy of breasts. However, physical sex
characteristics that are not completely reversible with GnRH
agonists include large breasts as well as short stature.
Normal pubertal development resumes immediately upon
termination of GnRH agonist therapy. Treatment with crosssex hormone therapy may be initiated at 16 years of age.
Surgical Options
Sex reassignment surgery may be recommended for patients
following at least one year of compliant cross-sex hormone
therapy.3 Surgical sex reassignment options for FtM
transgender patients include subcutaneous mastectomy, hysterectomy/salpingo-oophorectomy, reconstruction of the
urethra which may be combined with phalloplasty, vaginectomy, scrotoplasty and implantation of erection and/or testicular prosthesis.1 Additional aesthetic procedures may also
be performed such as liposuction, lipofilling, pectoral implants and voice surgery. Patients who undergo gonadectomy will need hormone replacement therapy in addition to
postsurgery monitoring in order to prevent adverse events
due to chronic hormone deficiency. Patients who do not continue hormone therapy after gonadectomy will be at an increased risk for bone loss due to a decline in estrogen and
testosterone levels.
Preventive Care-Disease Risk Factors
The use of cross-sex hormone therapy has raised concerns

Table 1. Testosterone Doses in Female-to-Male Transgender Patients.21

Formulation

Dosage

Testosterone enanthate (generic only) or testosterone
cypionate (Depo®-Testosterone) IM (intramuscular)
injection

150-200 mg IM every 2 weeks
or 75-100 mg/week

Testosterone undecanoate IM injection (Aveed®)

750 mg (3 mL) IM initially, 750 mg IM after 4 weeks, then
750 mg IM every 10 weeks thereafter

Testosterone 1 % gel (AndroGel®· Testim®, Vogelxo™)

5-10 g/day

Testosterone patch (Androderm®)

Apply 1 or 2 patches daily to deliver 5-10 mg over 24 hours
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about whether administration of hormonal agents may alter
an individual's risk factors for certain diseases. Conditions of
particular concern in FtM patients include cardiovascular
health, bone density and cancer risk.
Cardiovascular Health: Testosterone therapy in FtM
transgender patients has been found to cause a decrease in
high-density lipoprotein levels and an increase in triglyceride levels resulting in a lipid profile that is more atherogenic,
but data is conflicting regarding whether the change in lipid
profile has a negative influence on cardiovascular health.23
For example, Van Kesteren et al. found no difference in cardiovascular outcomes in FtM patients compared to the general
population,24 whereas a systematic review and meta-analysis
of 10 studies that included FtM groups found that data were
insufficient to evaluate cardiovascular outcomes.23 More
research is needed to evaluate the effect that cross-sex
hormone treatment has on cardiovascular disease risk.3
Therefore, since optimum management of cardiovascular
risk factors in FtM transgender patients is currently
unknown, clinicians should follow currently established
guidelines for cardiovascular management, such as the
National Cholesterol Education Program's Adult Treatment
Panel III or the practice guidelines from the American
College of Cardiology/American Heart Association.3,2s-26
These publications offer guidance on how to assess an individual's risk of atherosclerotic cardiovascular disease and
how to treat dyslipidemias. However, the clinical guidelines
for transgender treatment do not suggest whether physicians
should use the patient's biological sex or gender identity
when assessing cardiovascular risk.
Bone Density: Bone mineral density (BMD) should be
measured at baseline before cross-sex hormone administration for FtM transgender patients who also have risk factors
for fractures due to osteoporosis.3 Risk factors include previous fracture, family history of osteoporosis, use of glucocorticoids and prolonged hypogonadism. Appropriate dosing of
testosterone is important for maintaining BMD in FtM patients.27 In a study examining BMD and bone metabolism in
transgender patients, BMD measurements were reportedly
the same after one year of testosterone administration
compared to baseline, but BMD declined after long-term examination at 28 to 63 months. Due to the decline in estrogen
levels, FtM transgender patients may experience decreased
BMD over time, so testosterone dosing needs to be sufficient
to maintain bone mass. Serum luteinizing hormone (LH) levels may be a useful biological marker for assessing whether
testosterone dose is adequate to maintain BMD, as LH levels
were found to be inversely related to BMD.
Cancer Risk: Cross-sex testosterone therapy may increase
the risk of endometrial and ovarian cancer. A proposed
mechanism for the elevation of endometrial cancer risk is the
conversion of testosterone to estrogen which in turn causes
endometrial hyperplasia and may progress to endometrial
carcinoma.3.2s However, no cases of endometrial cancer have
been reported in FtM patients.3 The increased risk of ovarian
cancer may be due to the increased expression of androgen
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receptors in the ovaries after long-term testosterone administration, but this cause and effect relationship is not yet fully
established.29 Estrogen receptors may also play a role in increasing ovarian cancer risk because of the excess estrogen
that exists after the conversion of testosterone to estrogen.
Three cases of ovarian cancer development in FtM
transgender patients have been reported: two cases occurred
in the Netherlands and the third occurred in Rhode Island,
USA.30-31 In all three cases, the medical practitioners were
unable to determine whether the ovarian cancer was caused
by testosterone therapy. These risks of endometrial and
ovarian cancer may be eliminated if the patient chooses to
undergo total hysterectomy and oophorectomy.3
Clinical and Laboratory Monitoring
The Endocrine Society's clinical practice guidelines recommend that FtM transgender patients on cross-sex hormone
therapy should be monitored by a physician every two to
three months for the first year of therapy and then once or
twice per year during subsequent years.3 Physical exams
during these visits should include measurement of weight,
blood pressure and complete blood count as well as monitoring of renal function, hepatic function, lipid levels and glucose levels. In addition, FtM transgender patients should be
monitored for signs of appropriate virilization as well as adverse reactions from testosterone therapy. Estradiol levels
should be measured until there has been no menstruation for
six months. For FtM patients, estradiol levels should be below 50 pg/mL. Bone mineral density should be measured
starting at 60 years of age as well as in patients who are not
adherent to hormone therapy. Additionally, patients should
receive an annual pap smear if cervical tissue is still present.
Guidelines also recommend that if a FtM patient has not had
a mastectomy, the patient should receive mammograms according to the current recommendations from the American
Cancer Society. It is important to realize that these screenings may be emotionally as well as physically painful to FtM
patients since they directly conflict with the patient's gender
identity.1 Health care providers should be aware of the distress FtM transgender patients may feel about receiving a
pap smear or mammogram, but providers still need to reaffirm the necessity of such screenings for protecting the patient's health.
Role of the Pharmacist
With the expanding role of the pharmacist, pharmacists may
have the opportunity to assist with transition of their
transgender patients. Transition can be defined in two ways:
first, it can refer to the time period during which the individual undergoes change in his or her physical, legal and social
characteristics of the gender opposite to one's biological sex
in order to align with one's gender identity; and second, it
can refer to the consistent process of physical and psychological adaptation.3 Pharmacists who are involved should know
a general timeline of characteristics that may manifest themselves in transgender individuals transitioning from MtF or
FtM. Figure 2 contains estimates for when certain feminizing
(Figure 2A) or masculinizing (Figure 28) effects appear in
transgender individuals.24,32-33
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Figure 2. Timeline of Feminizing Effects Observed in MtF Patients on Hormonal Therapy (2A) and Timeline of
Masculinizing Effects Observed in FtM Patients on Hormonal Therapy (2B). 24, 32-33

Figure 2A.

~:_i~3 ~on~h:s rafter
start of trarisition
•Reduced libido
•Reduced
incidence of
non-sexual
induced
erections

•Fat
Redistribution
to buttocks,
thighs, and hips
•Change in
muscle mass
and strength
•Change in skin
composition
•Reduced testicle
size

•Reduced body
hair, excluding
scalp*

Figure 2B.

• Increased acne
and skin
oiliness
• Redistribution
of body fat
• Cessation of
menses
• Enlargement of
the clitoris
• Vaginal Atrophy

• Gain of muscle
mass and
strength
•Deepened
voice/tone
• Loss of Scalp
Hair
• Increased facial
or body hair

Please note: These timelines are only a reference, and individuals undergoing transitional therapy may experience these
characteristics earlier or later than what has been described. Individuals should consult their prescriber if they believe their
therapy is ineffective.
*Further actions such as laser treatment may be needed to remove all male sexual hair.
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Being able to recognize these characteristics is important as
they give pharmacists and clinicians markers in the timeline
of a patient's transition. Additionally, lab values including
hormone levels pertaining to cross-hormonal therapy or
transitional therapy also play an important role in a patient's
transition especially in the first year.3
All MtF patients should be evaluated in general every two to
three months within the first year to ensure a stable and safe
transition.34 Similarly, FtM patients should be evaluated
along the same general timeline as MtF patients with one
every two to three months for the first year and annual or
biannual follow ups after the first year. As with MtF patients,
serum testosterone should be measured about every two to
three months until at a normal physiological range equal to a
biological male.35 The transgender population remains an
underserved population in the medical field. By educating
health care professionals on the therapies and issues surrounding an individual undergoing transition, the stigma
surrounding transgender individuals can be eliminated. 36
Questions should be asked in regard to issues surrounding
transgenderism but to a point that they are addressed in a
sensitive and professional manner. Keep in mind, not all individuals who are transgender struggle with issues pertaining
to gender.37 Pharmacists are usually the first health care professional an individual may approach for help, thus being
able to triage a situation with a transgender patient may be
very important for that individual. In cases where pharmacists are beyond their resources to help a transgender
patient, the patient should be referred to their physician or a
mental health professional experienced in gender identity
issues.
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